AI & RoboticsNews

AI Weekly: A biometric surveillance state is not inevitable, says AI Now Institute

In a new report called “Regulating Biometrics: Global Approaches and Urgent Questions,” the AI Now Institute says that there’s a growing sense among regulation advocates that a biometric surveillance state is not inevitable. The release of AI Now’s report couldn’t be more timely. As the pandemic drags on into the fall, businesses, government agencies, and schools are desperate for…
Read more
AI & RoboticsNews

Myst AI claims its AI energy prediction technology boosts utilities’ reliability

Myst AI, a startup developing a predictive energy usage platform, today closed a $6 million funding round. The proceeds will be used to expand Myst’s “forecasting as a service” offering as it seeks to acquire new customers, a spokesperson told VentureBeat via email. The pandemic has prompted governments to institute shelter-in-place orders, quarantine mandates, and business closures. As…
Read more
AI & RoboticsNews

Google Maps is improving travel ETAs with DeepMind AI

Google Maps helps users navigate over one billion kilometers in more than 200 countries and territories daily, and Google says its estimated time of arrival (ETA) predictions have been consistently accurate for over 97 percent of trips. That’s not good enough for Google…
AI & RoboticsNews

DeepMind claims its AI improved Google Maps travel time estimates by up to 50%

DeepMind today detailed a collaboration with Google that reportedly improved the accuracy of real-time driving ETAs in Google Maps and Google Maps Platform APIs by up to 50% in some regions, including Berlin, Jakarta, São Paulo, Sydney, Tokyo, and Washington D.C. Through the use of machine learning techniques, DeepMind claims it minimized traffic prediction inaccuracies by incorporating…
Read more
AI & RoboticsNews

Biofourmis raises $100 million for AI remote medical tools

Biofourmis, an AI health IT company based in Singapore, today announced it raised $100 million in a series C funding round led by SoftBank’s Vision Fund 2. CEO Kuldeep Singh Rajput said the company will use the proceeds to accelerate expansion, advance therapeutics pipelines, develop care pathways, and drive integration with health system, hospital, pharmaceutical, and research clients.
Read more